News & Updates

As an IP Hatch award winner, our CEO Amin Rigi presented at Panasonic's Demo Day in Japan, a milestone moment for Eyesight Electronics. The visit included meetings with Panasonic CTO Tatsuo Ogawa, Head of Digital Transformation Hiroshi Saijou, and IP Management CEO Shingo Wakashiro.

The team also visited Futrworks and the 5G X Lab (supported by SoftBank), exploring how next-generation connectivity and innovation infrastructure could support our mission of addressing amblyopia, which affects more than 120 million people globally. The IP Hatch programme awarded us a Panasonic patent that complements our existing US patent portfolio.

Eyesight Electronics announced our inclusion in the 2025 ABHI Middle East Accelerator on LinkedIn, emphasising our founding vision: "every individual has access to timely and innovative vision care solutions." The ABHI programme is specifically designed to help UK healthtech companies build partnerships and market access in the Gulf region's rapidly growing healthcare sector.

In a landmark clinical result, a patient with 6/60 vision, classified as legally blind in the United States, has regained functional sight using our home-based AmblyoFix therapy. The patient achieved a 22% improvement in just 2.5 weeks, 40% after 9 weeks, and over 52% after 14 weeks of treatment.

These results significantly outpace leading VR-based alternatives, which typically show around 18% improvement over the same timeframe. Unlike traditional eye patching, which only forces the weaker eye to work and has just 50% compliance among young patients, AmblyoFix uses specially designed 3D glasses and interactive games to train both eyes simultaneously, improving depth perception, hand-eye coordination, and binocular vision.

Founded in 2019 by Dr. Faiz Rigi (ophthalmologist) and Amin Rigi (bioengineer, University of Edinburgh PhD), Eyesight Electronics holds one granted US patent with another pending, and was awarded the IP Hatch prize including a Panasonic patent.

We're not just improving vision. We're giving people their confidence, independence, and quality of life back. Our dream is to ensure no one loses sight to a treatable condition. - Amin Rigi, CEO

Tomorrow's World Today, a well-known technology and innovation publication, has featured AmblyoFix in their Health and Wellness section, describing our approach as a "revolution in vision therapy." The independent editorial, not a press release, highlights how our combination of 3D glasses and interactive digital games is transforming treatment for over 100 million people affected by amblyopia worldwide.

The piece notes that traditional eye patching has been the standard for decades despite its well-documented limitations, and positions AmblyoFix as a breakthrough that "far outpaces traditional methods." Being featured in an independent innovation publication alongside their "World of Innovation" editorial series reflects the broader recognition our approach is gaining.

We're proud to announce that our clinical trial (NCT07240311) is now actively recruiting participants. Registered on ClinicalTrials.gov, this study represents a critical step in building the formal clinical evidence base for AmblyoFix's approach to amblyopia treatment.

While our preliminary results have been compelling, with individual patients showing over 52% vision improvement, a controlled clinical trial will provide the rigorous, peer-reviewed evidence needed to support broader adoption by eye care professionals worldwide. We believe strongly in evidence-based medicine and are committed to meeting the highest standards of clinical validation.

We're thrilled to have been selected for the 2025 ABHI Middle East Accelerator cohort. The Association of British HealthTech Industries (ABHI) is the UK's leading healthtech trade association, and their Middle East Accelerator programme connects innovative UK health technology companies with healthcare systems and partners across the Gulf region.

This selection reflects our growing international footprint and our commitment to making vision therapy accessible regardless of geographic location. The programme will help us build partnerships and pathways to deliver AmblyoFix to communities across the Middle East, a region with significant unmet need in vision care.